The Black Hole of Immune Checkpoint Blocking Therapy for Gastric Cancer: Hyperprogressive Disease
Cancer Science · 2025
DOI: 10.1111/cas.70143 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Science, 2025. Verfasst von Zhuan-Fang Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Lanzhou University Second Hospital, Lanzhou, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Major scientific research project for scientific and technological innovation in the health industry of Gansu Province, National Natural Science Foundation of China, Science and Technology Project of Chengguan District of Lanzhou City.
Abstract (Originalsprache)
In recent years, immune checkpoint inhibitors (ICIs) represented by PD‐1/PD‐L1 monoclonal antibodies have shown some good efficacy in various solid tumors such as gastric cancer. However, only about less than 30% of patients benefit from ICIs, and some patients experience rapid tumor growth posttreatment, known as hyperprogressive disease (HPD). Collectively, the overall survival of HPD patients is significantly shorter compared to patients with traditional disease progression, and there is no unified criterion for diagnosing HPD. Some biological mechanisms of HPD in gastric cancer caused by ICIs are still unclear, and factors associated with the occurrence of HPD are uncertain. Notably, it is believed that intrinsic factors, such as abnormal expression of oncogenic genes, and extrinsic factors, including remodeling of the tumor microenvironment, “drift” of immune cell subtypes, may be related to the occurrence of HPD in gastric cancer. Due to its immune stimulatory effects, ICIs may activate certain oncogenic pathways within the tumor, resulting in the appearance of tumor HPD phenomena through increased expression and mutations of some genes, as well as disruption of the balance between immune cells and tumor cells in the tumor microenvironment. Therefore, this review summarizes the mechanisms, predictive biomarkers, prevention, and treatment methods of HPD after immune checkpoint blockade therapy, providing a theoretical basis for making a judgment on the efficacy of ICI treatment for gastric cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lanzhou University Second Hospital, Lanzhou, China.
- Department of Surgical Oncology, Lanzhou University Second Hospital, Lanzhou, China.
- Key Laboratory of the Environmental Oncology of Gansu Province, Lanzhou, China.
- Humanized Animal Model Laboratory, Lanzhou University Second Hospital, Lanzhou, China.
- Shanghai General Hospital, Shanghai, China.
ORCID-Profile: Hao Chen
Förderung
- Major scientific research project for scientific and technological innovation in the health industry of Gansu Province
- National Natural Science Foundation of China
- Science and Technology Project of Chengguan District of Lanzhou City
- Key Project of Science and Technology in Gansu province
- General Project of Gansu Province Joint Research Fund
- Medical Research Innovation Ability Improvement Project of Lanzhou University
- Key Talents Project of Gansu Province
- Excellent Textbook Cultivation Project of Lanzhou University
Zitieren
APA
Wang, Z. F., Ma, C. H., Maswikiti, E. P., Han, Q. Y., He, L. J., Liu, B., Han, Z. J., & Chen, H. (2025). The Black Hole of Immune Checkpoint Blocking Therapy for Gastric Cancer: Hyperprogressive Disease. Cancer Science. https://doi.org/10.1111/cas.70143
Vancouver
Wang ZF, Ma CH, Maswikiti EP, Han QY, He LJ, Liu B, et al. The Black Hole of Immune Checkpoint Blocking Therapy for Gastric Cancer: Hyperprogressive Disease. Cancer Science. 2025. doi:10.1111/cas.70143
BibTeX
@article{Wang2025,
author = {Wang, Zhuan-Fang and Ma, Chen-Hui and Maswikiti, Ewetse Paul and Han, Qin-Ying and He, Li-Juan and Liu, Ben and Han, Zhi-Jian and Chen, Hao},
title = {The Black Hole of Immune Checkpoint Blocking Therapy for Gastric Cancer: Hyperprogressive Disease},
journal = {Cancer Science},
year = {2025},
doi = {10.1111/cas.70143}
}
EUVIMED